Please login to the form below

Not currently logged in
Email:
Password:

Type 2 diabetes market set to soar to $64bn by 2026

Rising prevalence, progressive nature and diagnosis of the condition behind the surge

money

The type 2 diabetes market is set to surge, rising from $28.6bn in 2016 to an estimated $64bn in 2026.

The seven major markets of the US, France, Germany, Italy, Spain, UK and Japan are expected to see 8.4% compound annual growth, driven by the condition’s rising prevalence, progressive nature and diagnosis.

The rise in disease-related comorbidities will also play a part in the projected market boost as more patients require multiple drug therapies, according to research and analysis group GlobalData.

Managing healthcare analyst Jesus Cuaron said: “All currently available treatments for type 2 diabetes are initially effective and reduce complication rates, but they lack the ability to maintain glycaemic control in the long term because of the progressive nature of pancreatic B-cell dysfunction.

“This represents one of the highest unmet needs in the type 2 diabetes space and demonstrates that the market has a significant growth opportunity for new patent-protected products that successfully address underlying disease pathology, cardiovascular concerns or compliance issues.”

Article by
Gemma Jones

17th August 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics